Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2033-03-03
Target enrollment:
Participant gender:
Summary
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that
PD-1 treatment added to salvage surgery could further decrease the rate of disease
progression and improve the survival outcome of patients with resectable locally recurrent
nasopharyngeal carcinoma compared with those treated with salvage surgery alone.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
First Affiliated Hospital, Sun Yat-Sen University First People's Hospital of Foshan Nanfang Hospital of Southern Medical University Tenth Affiliated Hospital, Sun Yat-sen University Zhongshan People's Hospital, Guangdong, China